Verve Therapeutics, Inc. Stock News

Verve Therapeutics (VERV) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.84 per share a year ago.

BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing med

The average of price targets set by Wall Street analysts indicates a potential upside of 93.5% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable,

Cathie Wood has been buying a lot of Verve Therapeutics stock recently. It's a gene-editing biotech that's just starting its first clinical trials.

Verve, which was founded in 2018 and went public in June 2021, is developing gene-editing treatments, delivered through a single, intravenous infusion, for atherosclerotic cardiovascular disease.

Verve's (VERV) shares rise on collaboration with Eli Lilly to develop gene editing treatment for cardiovascular disease.

Verve Therapeutics (VERV) came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.62 per share a year ago.

A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medi

Verve Therapeutics, Inc. is developing a CRISPR-based editing gene therapy for cardiovascular diseases. Verve's lead assets are VERVE-101 for HeFH and ASCVD and VERVE-201 for HoFH.

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attr

Verve Therapeutics is a gene editing company focused on revolutionizing the treatment of cardiovascular diseases. The company's research focuses on two genes, PCSK9 and ANGPTL3 - the lead product cand

Verve Therapeutics has been stuck with a clinical hold. There is no good reason the hold will not be lifted, say within a year or less.

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease

The growth-focused money manager is making moves.